We collect, monitor, analyse and interpret information on the uptake of patient screening for multi-drug resistant organisms (MDRO) on admission to hospital. This screening is key to reducing the development and spread of infections in healthcare. Early detection of high-risk patients – using a clinical risk assessment (CRA) based approach – allows early isolation while microbiological samples are tested. This reduces the opportunity for transmission if a patient is colonised or infected.
To ensure that CRA based-screening is as effective as universal screening, a minimum of 90% compliance with application of the CRA is required for methicillin-resistant Staphylococcus aureus (MRSA) Screening and all patients admitted to acute hospitals should be screened by CRA for carbapenemase producing-Enterobacteriaceae (CPE).
Find the two national acute hospital admission MDRO screening policies for:
- meticillin resistant Staphyloccus aureus (MRSA) screening
- carbapenemase-producing Enterobacteriaceae (CPE) screening